## 12 month risk of congenital malformations, deformations, and chromosomal abnormalities in patients with T2DM and OUD (Comparision between matched semaglutide vs other anti-diabetes medications groups)

Size/group	Exposure group	Comparison group	cases (overall risk) (Exposure)	cases (overall risk (Comparison)	)		HR (95% CI)
2,568	semaglutide	insulins	124 (4.8%)	135 (5.3%)	-■	H	0.90 (0.71–1.15)
2,427	semaglutide	metformin	119 (4.9%)	128 (5.3%)	<b>├</b> -		0.93 (0.73–1.20)
1,652	semaglutide	DPP-4i	84 (5.1%)	84 (5.1%)	<b>⊢</b> •	<b>-</b>	1.00 (0.74–1.35)
2,167	semaglutide	SGLT2i	109 (5.0%)	106 (4.9%)	<b>⊢</b> •	 	1.01 (0.77–1.32)
1,984	semaglutide	SU	96 (4.8%)	91 (4.6%)	$\vdash$	<b>■</b> —	1.06 (0.79–1.41)
724	semaglutide	TZD	21 (2.9%)	21 (2.9%)	<b> </b>	<b>-</b>	0.99 (0.54–1.80)
2,128	semaglutide	other GLP-1RAs	98 (4.6%)	95 (4.5%)	<u> </u>	<b>-</b>	1.05 (0.79–1.39)
					0.20 0.30 0.50 0.80 Hazard R	2.0 3.00 5.00 atio (HR)	0